BYNDER
23.1.2024 13:45:26 CET | Business Wire | Press release
Bynder, a global leader in enterprise digital asset management (DAM) has today released data highlighting the strategic importance of enterprise DAM and content for brands looking to grow amidst market uncertainty and economic headwinds.
- Increased market demand highlighted by record number of new business logos and customer expansion in Q4 2023 as brands continue to see content as a strategic enabler
- AI functionality drives demand and is included in nearly 50% of new business deals in Q4
- Customers report time savings of 30-40% utilizing AI, and are 2x more likely to find the assets they need
- Leading indicators show significant growth in enterprise DAM usage and integration as businesses look to improve efficiency and drive increased ROI from their investments in content.
The need to deliver customers an exceptional content experience is driving more brands to look for efficiency, speed to value and increased ROI in the creation, management and distribution of content. In this landscape an enterprise DAM platform becomes mission critical as organizations compete for share of wallet in a growing and increasingly crowded digital and retail marketplace.
Recent AI innovations have highlighted Bynder’s market leadership, and its host of AI and automation capabilities have led to continued growth in new business, customer adoption and platform usage. The latest of these innovations, AI Search Experience, enables identification of similar assets and text in images, as well as the ability to search using images and identify duplicate assets. These capabilities allow teams to find, reuse and deliver more relevant content, quicker and more effectively.
Brittany Chase, Project Specialist at Architecture and Planning firm, HFA, said, “AI Search Experience would save between 30% and 40% of time from not having to upload and tag assets that already exist in the DAM.” In addition, a US-based healthcare company attributed a minimum saving of 6 hours a week to the new AI functionality, enabling team members to focus on more strategic initiatives.
As organizations continue to use content as a strategic advantage, usage of enterprise DAM enables efficiency across the entire content lifecycle. Across 2023, Bynder saw a 38% year-on-year growth in the number of assets stored on their platform, and a 250% increase in delivery of assets from Bynder’s platform to websites. Over the holiday season Bynder saw an exponential uplift in assets created, stored and distributed as brands looked to deliver exceptional digital shopping experiences.
Bynder’s hosts the largest marketplace of out of the box integrations and in 2023 this grew 38%. In addition, Bynder reported a 176% increase in API calls to their platform showing the criticality of a connected ecosystem to improve content operations.
Bynder CEO Bob Hickey said, “As digital commerce continues to accelerate, brands need to provide a seamless content experience to their customers. Our continued year-on-year growth, culminating in a record Q4 in 2023, indicates that investment in an enterprise DAM platform is vital for those looking to deliver content experiences while gaining compelling value and ROI from their content operations and IT investments.
“We’re pleased to see that our ongoing innovation and market leadership in AI has further driven our growth in Q4, highlighting that AI has become a strategic tool for marketers looking to streamline content operations and improve customer experience.”
For more information on Bynder and its AI capabilities, please visit https://www.bynder.com/en/solutions/initiatives/ai-automation/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123344937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom